Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease
Copyright © 2023 by The American Association of Immunologists, Inc..
Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation. Human platelets express the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R agonists decrease lung IL-33 release and airway hyperresponsiveness in mouse asthma models. We hypothesized that GLP-1R agonists reduce platelet activation and downstream platelet-mediated airway inflammation in AERD. GLP-1R expression on murine platelets was assessed using flow cytometry. We tested the effect of the GLP-1R agonist liraglutide on lysine-aspirin (Lys-ASA)-induced changes in airway resistance, and platelet-derived mediator release in a murine AERD model. We conducted a prospective cohort study comparing the effect of pretreatment with liraglutide or vehicle on thromboxane receptor agonist-induced in vitro activation of platelets from patients with AERD and nonasthmatic controls. GLP-1R expression was higher on murine platelets than on leukocytes. A single dose of liraglutide inhibited Lys-ASA-induced increases in airway resistance and decreased markers of platelet activation and recruitment to the lung in AERD-like mice. Liraglutide attenuated thromboxane receptor agonist-induced activation as measured by CXCL7 release in plasma from patients with AERD and CD62P expression in platelets from both patients with AERD (n = 31) and nonasthmatic, healthy controls (n = 11). Liraglutide, a Food and Drug Administration-approved GLP-1R agonist for treatment of type 2 diabetes and obesity, attenuates in vivo platelet activation in an AERD murine model and in vitro activation in human platelets in patients with and without AERD. These data advance the GLP-1R axis as a new target for platelet-mediated inflammation warranting further study in asthma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:211 |
|---|---|
| Enthalten in: |
Journal of immunology (Baltimore, Md. : 1950) - 211(2023), 12 vom: 15. Dez., Seite 1806-1813 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Foer, Dinah [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2023 Date Revised 07.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4049/jimmunol.2300102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363626018 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363626018 | ||
| 003 | DE-627 | ||
| 005 | 20240207232059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4049/jimmunol.2300102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1283.xml |
| 035 | |a (DE-627)NLM363626018 | ||
| 035 | |a (NLM)37870292 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Foer, Dinah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2023 | ||
| 500 | |a Date Revised 07.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by The American Association of Immunologists, Inc. | ||
| 520 | |a Platelets are key contributors to allergic asthma and aspirin-exacerbated respiratory disease (AERD), an asthma phenotype involving platelet activation and IL-33-dependent mast cell activation. Human platelets express the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R agonists decrease lung IL-33 release and airway hyperresponsiveness in mouse asthma models. We hypothesized that GLP-1R agonists reduce platelet activation and downstream platelet-mediated airway inflammation in AERD. GLP-1R expression on murine platelets was assessed using flow cytometry. We tested the effect of the GLP-1R agonist liraglutide on lysine-aspirin (Lys-ASA)-induced changes in airway resistance, and platelet-derived mediator release in a murine AERD model. We conducted a prospective cohort study comparing the effect of pretreatment with liraglutide or vehicle on thromboxane receptor agonist-induced in vitro activation of platelets from patients with AERD and nonasthmatic controls. GLP-1R expression was higher on murine platelets than on leukocytes. A single dose of liraglutide inhibited Lys-ASA-induced increases in airway resistance and decreased markers of platelet activation and recruitment to the lung in AERD-like mice. Liraglutide attenuated thromboxane receptor agonist-induced activation as measured by CXCL7 release in plasma from patients with AERD and CD62P expression in platelets from both patients with AERD (n = 31) and nonasthmatic, healthy controls (n = 11). Liraglutide, a Food and Drug Administration-approved GLP-1R agonist for treatment of type 2 diabetes and obesity, attenuates in vivo platelet activation in an AERD murine model and in vitro activation in human platelets in patients with and without AERD. These data advance the GLP-1R axis as a new target for platelet-mediated inflammation warranting further study in asthma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide-1 Receptor |2 NLM | |
| 650 | 7 | |a Interleukin-33 |2 NLM | |
| 650 | 7 | |a acetylsalicylic acid lysinate |2 NLM | |
| 650 | 7 | |a XAN4V337CI |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Receptors, Thromboxane |2 NLM | |
| 700 | 1 | |a Amin, Taneem |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Yumi |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Chunli |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Newcomb, Dawn C |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Juying |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Snyder, William E |e verfasserin |4 aut | |
| 700 | 1 | |a McGill, Alanna |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Anabel |e verfasserin |4 aut | |
| 700 | 1 | |a Laidlaw, Tanya M |e verfasserin |4 aut | |
| 700 | 1 | |a Niswender, Kevin D |e verfasserin |4 aut | |
| 700 | 1 | |a Boyce, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Cahill, Katherine N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology (Baltimore, Md. : 1950) |d 1945 |g 211(2023), 12 vom: 15. Dez., Seite 1806-1813 |w (DE-627)NLM000018554 |x 1550-6606 |7 nnns |
| 773 | 1 | 8 | |g volume:211 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:1806-1813 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4049/jimmunol.2300102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 211 |j 2023 |e 12 |b 15 |c 12 |h 1806-1813 | ||